NYSEARCA:GERM

Amplify Treatments, Testing and Advancements ETF (GERM) Price, Holdings, & News

$16.68
-0.22 (-1.30%)
(As of 04/24/2024 ET)
Today's Range
$16.68
$16.78
50-Day Range
$16.34
$18.95
52-Week Range
$15.67
$21.70
Volume
1,041 shs
Average Volume
2,116 shs
Market Capitalization
$9.17 million
Assets Under Management
$9.34 million
Dividend Yield
0.84%
Net Expense Ratio
0.68%
GERM stock logo

About Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM)

The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.

GERM Stock Price History

GERM ETF News Headlines

ETFMG Treatments Testing and Advancements ETF
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
GERM ETFMG Treatments, Testing and Advancements ETF
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Lactose Intolerance Treatment Market Growth by 2031
See More Headlines
Receive GERM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amplify Treatments, Testing and Advancements ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
Amplify
Fund Name
Amplify Treatments, Testing and Advancements ETF
Tax Classification
Regulated Investment Company
Current Symbol
NYSEARCA:GERM
Inception Date
6/17/2020
Fund Manager
Charles Ragauss, Qiao Duan
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
Prime Treatments, Testing and Advancements Index
Category
Strategy
Focus
Theme
Development Level
Blended Development
Region
Global
Number of Holdings
57

Fund Statistics

Assets Under Management
$9.34 million
Average Daily Volume
$0.00
Discount/Premium
-0.09%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Amplify Investments LLC
Custodian
U.S. Bank, N.A.
Distributor
Foreside Fund Services, LLC
Transfer Agent
U.S. Bancorp Fund Services, LLC
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
N/A
Short Interest
100 shs

Miscellaneous

Beta
0.87
Creation Unit
50,000
Creation Fee
$300.00
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Amplify Treatments, Testing and Advancements ETF Expenses

TypeGERMTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.68%0.57%0.54%0.50%0.51%
Other Expenses0.00%0.72%0.54%0.64%0.58%
Total Expense0.68%0.72%0.70%0.74%0.70%
Fee Waiver0.00%-0.76%-0.55%-0.68%-0.57%
Net Expense0.68%0.59%0.60%0.57%0.58%

Amplify Treatments, Testing and Advancements ETF (GERM) Holdings & Exposure

GERM Sector Exposure

GERM Industry Exposure


GERM ETF - Frequently Asked Questions

How have GERM shares performed in 2024?

Amplify Treatments, Testing and Advancements ETF's stock was trading at $19.56 at the beginning of the year. Since then, GERM shares have decreased by 14.7% and is now trading at $16.68.
View the best growth stocks for 2024 here
.

What does GERM invest in?

Amplify Treatments, Testing and Advancements ETF is a equity fund issued by Amplify. GERM focuses on theme investments and follows the Prime Treatments, Testing and Advancements Index. The fund's investments total to approximately $9.34 million assets under management.

What stocks does Amplify Treatments, Testing and Advancements ETF hold?
What is the management fee for Amplify Treatments, Testing and Advancements ETF?

Amplify Treatments, Testing and Advancements ETF's management fee is 0.68% and has no other recorded expenses or fee waivers. The net expense ratio for GERM is 0.68%.

What other stocks do shareholders of Amplify Treatments, Testing and Advancements ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amplify Treatments, Testing and Advancements ETF investors own include Village Farms International (VFF), Charlotte's Web (CWBHF), 3 Sixty Risk Solutions (PTVYF), Inovio Pharmaceuticals (INO), Moderna (MRNA), PayPal (PYPL), AbbVie (ABBV), Auxly Cannabis Group (CBWTF).

How do I buy shares of Amplify Treatments, Testing and Advancements ETF?

Shares of GERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEARCA:GERM) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners